Cross-topic event
LIBRETTO-432 at ASCO plenary and in NEJM: adjuvant selpercatinib cuts early RET fusion-positive NSCLC EFS risk by 83%
Jun 1, 20262 reports
Jun 1, 2026
Sciencedesk view
LIBRETTO-432 at ASCO plenary and in NEJM: adjuvant selpercatinib cuts early RET fusion-positive NSCLC EFS risk by 83%
Per Lilly, BioSpace, and Newswise (June 1, 2026), global Phase III LIBRETTO-432 was presented at ASCO and published in NEJM: 151 stage IB–IIIA RET fusion-positi…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
Lilly Retevmo adjuvant therapy: 83% lower recurrence/death risk in early RET fusion-positive lung cancer
Per BioSpace (May 31/June 1, 2026), phase 3 LIBRETTO-432 in early (IB–IIIA) RET fusion-positive NSCLC showed adjuvant selpercatinib (Retevmo) vs. placebo met th…
READ THE DAY'S DIGEST →